⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
SYNGENE - Swing Trade Analysis with AI Signals
Back to ListHere’s the structured swing trade analysis for SYNGENE based on the provided parameters
Swing Trade Rating: 3.5
| Stock Code | SYNGENE | Market Cap | 17,756 Cr. | Current Price | 440 ₹ | High / Low | 729 ₹ |
| Stock P/E | 49.1 | Book Value | 117 ₹ | Dividend Yield | 0.28 % | ROCE | 10.0 % |
| ROE | 7.74 % | Face Value | 10.0 ₹ | DMA 50 | 450 ₹ | DMA 200 | 525 ₹ |
| Chg in FII Hold | -1.05 % | Chg in DII Hold | 0.61 % | PAT Qtr | 154 Cr. | PAT Prev Qtr | 68.7 Cr. |
| RSI | 45.1 | MACD | -0.70 | Volume | 6,68,009 | Avg Vol 1Wk | 6,05,861 |
| Low price | 380 ₹ | High price | 729 ₹ | PEG Ratio | -5.83 | Debt to equity | 0.04 |
| 52w Index | 17.3 % | Qtr Profit Var | -11.8 % | EPS | 7.57 ₹ | Industry PE | 39.7 |
📈 Optimal Entry Price: Around 430–440 ₹ (near current support)
📉 Exit Strategy: If already holding, consider profit booking near 470–480 ₹ resistance zone. A stop-loss can be placed below 415 ₹.
Positive
- ✅ PAT of 154 Cr. vs 68.7 Cr. shows strong sequential improvement.
- ✅ EPS of 7.57 ₹ supports earnings visibility.
- ✅ Low debt-to-equity ratio (0.04), ensuring financial stability.
- ✅ DII holdings increased (+0.61%), reflecting domestic investor confidence.
- ✅ Stock trading close to 50 DMA (450 ₹), offering technical support.
Limitation
- ⚠️ High P/E of 49.1 compared to industry PE of 39.7, suggesting premium valuation.
- ⚠️ Weak ROCE (10.0%) and ROE (7.74%) indicate modest efficiency.
- ⚠️ RSI at 45.1 and MACD negative (-0.70) show weak momentum.
- ⚠️ PEG ratio of -5.83 highlights poor growth relative to valuation.
- ⚠️ 52-week index at 17.3% reflects significant underperformance relative to highs.
Company Negative News
- 📉 Quarterly profit variation (-11.8%) raises concerns about earnings consistency.
- 📉 FII holdings decreased (-1.05%), showing reduced foreign investor confidence.
Company Positive News
- 📈 Sequential PAT growth supports near-term momentum.
- 📈 Strong domestic institutional support with DII inflows.
- 📈 Low leverage provides financial stability.
Industry
- 🏭 Industry PE is 39.7, SYNGENE trades at 49.1 — slightly premium valuation.
- 🏭 Pharma & biotech sector supported by R&D demand and global outsourcing trends.
- 🏭 Sector outlook remains positive with innovation-driven growth opportunities.
Conclusion
🔎 SYNGENE is a moderate swing trade candidate with improving sequential profits and strong domestic support. Entry near 430–440 ₹ offers a reasonable risk-reward setup, while profit booking near 470–480 ₹ is advisable. Weak technical momentum and premium valuation warrant caution for traders.
Would you like me to extend this into a peer comparison with Biocon, Divi’s Labs, and Laurus Labs to benchmark SYNGENE’s valuation and momentum?